| OALBA0102 | Immune correlates analysis of the Imbokodo HIV-1 vaccine efficacy trial | Oral abstract session with live Q&A | Humoral immunity (including broadly neutralizing antibodies), Antibodies and B cells |
| EPA007 | Immune correlates of cell-associated HIV RNA levels in infected individuals undergoing long-term antiretroviral therapy | E-poster | Viral fitness, persistence and resistance |
| EPA011 | Immune preservation in HIV+ Viremic Non-Progressors is associated with downregulation of type-I IFN pathway and reduced activation of cytotoxic compartments | E-poster | Systemic immune activation and inflammation |
| EPB048 | Immunogenicity and safety of yellow fever vaccination in people living with HIV | E-poster | Opportunistic infections (excluding TB): Bacterial, non-TB mycobacterial, viral and parasitic infections |
| EPA091 | Immunogenicity of mRNA-1273 COVID-19 vaccination in PLWH after inadequate primary vaccination response | E-poster | SARS-Cov2 vaccines |
| PEMOA36 | Immunogenicity of the BNT 162b2 mRNA vaccine against COVID-19 variants in people living with HIV on antiretroviral therapy in Malaysia | Poster exhibition | SARS-Cov2 vaccines |
| EPA023 | Immunotherapeutic blockades targeting LAG-3 and PD-1 immune checkpoint inhibitors on invariant Natural Killer T cells: implications in chronic HIV infection | E-poster | Innate immunity (including NK cells) |
| EPD301 | Impact assessment of a Faith-based strategy for HIV mitigation in Nigeria | E-poster | Interventions to reduce stigma and discrimination |
| PESAE16 | Impact of a community health worker intervention on PrEP knowledge and utilization in Rakai, Uganda: a mixed methods assessment | Poster exhibition | Implementation science of scaling up prevention (including PrEP) |
| OAB0403 | Impact of a community-wide HIV test and treat intervention on population-level tuberculosis transmission in rural Uganda | Oral abstract session with live Q&A | Tuberculosis: Prevention, diagnosis, treatment |